Search - tctmd.com

Displaying 21 - 40 of 149

Sort: Relevancy | Date

Presentation JIM 2016

Intravenous P2Y12 Receptor Inhibitors With Powerful Oral Antiplatelets Are The New Best Option!

Presenter: Roxana Mehran

February 11, 2016

News Daily News

Ticagrelor Loading Dose Provides Faster Platelet Inhibition Than Clopidogrel in Ad Hoc PCI

L.A. McKeown

February 09, 2016

News Opinion Conversations in Cardiology

Conversations in Cardiology: Post-PCI Clopidogrel in CHAMPION PHOENIX Trial of Cangrelor

February 08, 2016

News Daily News

Interhospital Transfer for Acute MI Associated With Disruptions in Aftercare, More Readmissions

L.A. McKeown

January 27, 2016

News Daily News

Cath-Lab Complications: New Analysis Pinpoints Rate and Risks of Intraprocedural Thrombotic Events in ACS

Shelley Wood

January 21, 2016

News Daily News

Early Data Show Promise for Reversible, Fast-Acting, Antiplatelet Drug PZ-128

Caitlin E. Cox

December 20, 2015

News Daily News

Prometedores Primeros Datos para el Fármaco Antiplaquetario Reversible de Acción Rápida PZ-128

Caitlin E. Cox

December 20, 2015

News Daily News

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

Yael L. Maxwell

December 14, 2015

News Daily News

Según un Análisis los Beneficios Hemorrágico de la Bivalirudina Disminuyen a medida que Avanza la PCI

Todd Neale

December 14, 2015

News Daily News

Bivalirudin’s Bleeding Benefits Dampened by PCI Advances, Analysis Shows

Todd Neale

December 14, 2015

News Daily News

Many Lower-Income Patients Fail to Stick With Clopidogrel After PCI

Todd Neale

December 10, 2015

News Daily News

Newly Launched ACC Public Reporting Program Includes PCI Metrics, But No Mortality…For Now

L.A. McKeown

November 06, 2015

News Daily News

Medicare Part D Has Scant Effect on Outcomes for Acute MI Patients

Yael L. Maxwell

November 04, 2015

News Daily News

Morphine’s Worrisome Effects on Ticagrelor Affirmed in Pharmacokinetic Study

Shelley Wood

October 29, 2015

News Daily News

ADAPT-DES Analysis Reopens Debate Over Possible PPI, Clopidogrel Interaction

Caitlin E. Cox

October 28, 2015

Presentation TCT 2015

Cangrelor IV: Transitioning to Oral ADP Antagonists

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

Cangrelor III: Effects on Intraprocedural and Postprocedural Stent Thrombosis

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White, Philippe Généreux

October 15, 2015

Presentation TCT 2015

Cangrelor II: Perspectives on in Whom to Actually Use It

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

Cangrelor I: Data Essentials From the Champion Trials

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Presenter: Gary M. Ansel, Michael R. Jaff, Ori Ben-Yehuda

October 11, 2015

Advertisement

Intravenous P2Y12 Receptor Inhibitors With Powerful Oral Antiplatelets Are The New Best Option!

Ticagrelor Loading Dose Provides Faster Platelet Inhibition Than Clopidogrel in Ad Hoc PCI

Conversations in Cardiology: Post-PCI Clopidogrel in CHAMPION PHOENIX Trial of Cangrelor

Interhospital Transfer for Acute MI Associated With Disruptions in Aftercare, More Readmissions

Cath-Lab Complications: New Analysis Pinpoints Rate and Risks of Intraprocedural Thrombotic Events in ACS

Early Data Show Promise for Reversible, Fast-Acting, Antiplatelet Drug PZ-128

Prometedores Primeros Datos para el Fármaco Antiplaquetario Reversible de Acción Rápida PZ-128

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

Según un Análisis los Beneficios Hemorrágico de la Bivalirudina Disminuyen a medida que Avanza la PCI

Bivalirudin’s Bleeding Benefits Dampened by PCI Advances, Analysis Shows

Many Lower-Income Patients Fail to Stick With Clopidogrel After PCI

Newly Launched ACC Public Reporting Program Includes PCI Metrics, But No Mortality…For Now

Medicare Part D Has Scant Effect on Outcomes for Acute MI Patients

Morphine’s Worrisome Effects on Ticagrelor Affirmed in Pharmacokinetic Study

ADAPT-DES Analysis Reopens Debate Over Possible PPI, Clopidogrel Interaction

Cangrelor IV: Transitioning to Oral ADP Antagonists

Cangrelor III: Effects on Intraprocedural and Postprocedural Stent Thrombosis

Cangrelor II: Perspectives on in Whom to Actually Use It

Cangrelor I: Data Essentials From the Champion Trials

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content